Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by NB1017on Apr 26, 2019 1:26pm
104 Views
Post# 29675608

RE:ACB Initiated with Buy Rating by Desjardins Securities -News

RE:ACB Initiated with Buy Rating by Desjardins Securities -NewsI really like the closing comment, "Believing it is "emerging as the gold standard in the industry," Chu also gave Aurora Cannabis a buy rating with a $16.50 target, which exceeds the current consensus target of $13.91." I do believe we are going to see more and more upward targets leading up to next financial statement, especially if talks of potential deals come up.
AbrahamST wrote:

Desjardins recommend ACB and HEXO , HEXO is Flying.

09:46 AM EDT, 04/26/2019 (MT Newswires) -- Though industry sales numbers have been "somewhat underwhelming" following the first months since the legalization of adult-use cannabis in Canada, Desjardins Securities analyst John Chu said "the hype remains strong and for good reason as investors start looking at the market opportunity from a global perspective -- which is huge -- rather than simply a Canadian one," the Globe & Mail reported.

In a research report released Friday, Chu initiated coverage of Aurora Cannabis (ACB.TO), Canopy Growth (WEED.TO) and HEXO (HEXO.TO), emphasizing the potential stemming from an investing perspective that stretches beyond the Canadian border, pointing to the interest of major consumer packaged goods (CPG) companies and U.S. retailers, while also acknowledging the valuation difficulties investors are grappling with.

Believing it stands out with the most upside potential and a "cheap" current valuation, Chu initiated coverage of Gatineau, Que.-based HEXO with a buy rating and $14 target. The average target on the Street is currently $10.29, according to Thomson Reuters Eikon data.

"Despite its smaller size (capacity and market cap), HEXO joined the elite ranks quickly with the single largest supply deal with any province (Quebec) as well as its Molson Coors Canada JV, and is one of only a handful of companies with supply agreements with seven or more provinces in Canada," he said. "HEXO, with its track record for award-winning products and recognition for innovative products, should be a force to be reckoned with in the recreational segment."

Believing it is "emerging as the gold standard in the industry," Chu also gave Aurora Cannabis a buy rating with a $16.50 target, which exceeds the current consensus target of $13.91.



Bullboard Posts